Summary
The nitroimidazole antibiotic metronidazole has a limited spectrum of activity that encompasses various protozoans and most Gram-negative and Gram-positive anaerobic bacteria. Metronidazole has activity against protozoans like Entamoeba histolytica, Giardia lamblia and Trichomonas vaginalis, for which the drug was first approved as an effective treatment.
Anaerobic bacteria which are typically sensitive are primarily Gram-negative anaerobes belonging to the Bacteroides and Fusobacterium spp. Gram-positive anaerobes such as peptostreptococci and Clostridia spp. are likely to test sensitive to metronidazole, but resistant isolates are probably encountered with greater frequency than with the Gram-negative anaerobes. Gardnerella vaginalis is a pleomorphic Gram-variable bacterial bacillus that is also susceptible to metronidazole.
Helicobacter pylori has been strongly associated with gastritis and duodenal ulcers. Classic regimens for eradicating this pathogen have included metronidazole, usually with acid suppression medication plus bismuth and amoxicillin. The activity of metronidazole against anaerobic bowel flora has been used for prophylaxis and treatment of patients with Crohn’s disease who might develop an infectious complication.
Treatment of Clostridium difficile-induced pseudomembraneous colitis has usually been with oral metronidazole or vancomycin, but the lower cost and similar efficacy of metronidazole, coupled with the increased concern about imprudent use of vancomycin leading to increased resistance in enterococci, have made metronidazole the preferred agent here.
Metronidazole has played an important role in anaerobic-related infections. Advantages to using metronidazole are the percentage of sensitive Gram-negative anaerobes, its availability as oral and intravenous dosage forms, its rapid bacterial killing, its good tissue penetration, its considerably lower chance of inducing C. difficile colitis, and expense. Metronidazole has notable effectiveness in treating anaerobic brain abscesses.
Metronidazole is a cost-effective agent due to its low acquisition cost, its pharmacokinetics and pharmacodynamics, an acceptable adverse effect profile, and its undiminished antimicrobial activity. While its role as part of a therapeutic regimen for treating mixed aerobic/anaerobic infections has been reduced by newer, more expensive combination therapies, these new combinations have not been shown to have any therapeutic advantage over metronidazole.
Although the use of metronidazole on a global scale has been curtailed by newer agents for various infections, metronidazole still has a role for these and other therapeutic uses. Many clinicians still consider metronidazole to be the ‘gold standard’ antibiotic against which all other antibiotics with anaerobic activity should be compared.
Similar content being viewed by others
References
Cosar C, Julou L. Activité de l’(hydroxy-2-éthyl)-l-méthyl-2-nitro-5-imidazole (8823 R.P.) vis-à-vis des infections expérimentales à trichomonas vaginalis. Ann Inst Pasteur 1959; 96: 238–41
Müller M. Mode of action of metronidazole on anaerobic bacteria and protozoa. Surgery 1983; 93: 165–71
Korner, B, Jensen HK. Sensitivity of Trichomonas vaginalis to metronidazole, tinidazole, and nifuratel in vitro. Br J Vener Dis 1976; 52: 404–8
Ralph ED, Darwish R, Austin TW, et al. Susceptibility of Trichomonas vaginalis strains to metronidazole: response to treatment. Sex Transm Dis 1983; 10: 119–22
Smith RF, Domenico AD. Measuring the in vitro susceptibility of trichomonas vaginalis to metronidazole: a disk broth method. Sex Transm Dis 1980; 7: 120–4
Forsgren A, Wallin J. Tinidazole — a new preparation for Trichomonas vaginalis infections: I. Laboratory evaluation. Br J Vener Dis 1974; 50: 146–7
Meingassner JG, Havelec L, Mieth H. Studies on strain sensitivity of Trichomonas vaginalis to metronidazole. Br J Vener Dis 1978; 54: 72–6
Lossick JG, Müller M, Gorrell TE. In vitro drug susceptibility and dose of metronidazole required for cure in cases of refractory vaginal trichomoniasis. J Infect Dis 1986; 153: 948–55
Sears SD, O’Hare J. In vitro susceptibility of Trichomonas vaginalis to 50 antimicrobial agents. Antimicrob Agents Chemother 1988; 32: 144–6
Jokipii L, Jokipii AMM. In vitro susceptibility of Giardia lamblia trophozoites to metronidazole and tinidazole. J Infect Dis 1980; 141: 317–25
Farthing MJ, Inge PM. Antigiardial activity of the bile salt-like antibiotic sodium fusidate. J Antimicrob Chemother 1986; 17: 165–71
Vinayak VK, Mahajan RC, Chitkara NL. In vitro activity of metronidazole on the cysts of Entamoeba histolytica. Indian J Pathol Bacteriol 1975; 18: 61–4
Mahajan RC, Chitkara NL, Vinayak VK, et al. In vitro comparative evaluation of tinidazole and metronidazole on strains of Entamoeba histolytica. Ind J Pathol Bacteriol 1974; 17: 226–8
Tanowitz HB, Wittner M, Kress Y, et al. In vitro activity of metronidazole on Entamoeba histolytica in axenic culture. Trans R Soc Trop Med Hyg 1973; 67: 602–6
Vinayak VK, Mahajan RC, Chitkara NL. In vitro activity of metronidazole on the cysts of Entamoeba histolytica. Indian J Pathol Bacteriol 1975; 18: 61–4
Mahajan RC, Chitkara NL, Vinayak VK, et al. In vitro comparative evaluation of tinidazole and metronidazole on strains of Entamoeba histolytica. Indian J Pathol Bacteriol 1974; 17: 226–8
Shinn DLS. Metronidazole in acute ulcerative gingivitis. Lancet 1962; I: 1191
Tally FP, Sutter VL, Finegold SM. Metronidazole versus anaerobes: in vitro data and initial clinical observations. Calif Med 1972; 117: 22–6
Falagas ME, Gorbach SL. Clindamycin and metronidazole. Med Clin North Am 1995; 79: 845–67
Rissing JP, Moore Jr WL, Newman C, et al. Treatment of anaerobic infections with metronidazole. Curr Ther Res 1980; 27: 651–63
Collier J, Colhoun EM, Hill PL. A multicentre comparison of clindamycin and metronidazole in the treatment of anaerobic infections. Scand J Infect Dis 1981; Suppl. 26: 96–100
Study Group. An evaluation of metronidazole in the prophylaxis and treatment of anaerobic infections in surgical patients. J Antimicrob Chemother 1975; 1: 393–401
Eykyn SJ, Phillips I. Metronidazole and anaerobic sepsis. BMJ 1976; 2: 1418–21
Finegold SM. Metronidazole. Ann Intern Med 1980; 93: 585–7
Olsson-Liljequist B, Nord CE. In vitro susceptibility of anaerobic bacteria to nitroimidazoles. Scand J Infect Dis 1981; Suppl. 26: 42–5
Aldridge KE, Gelfand M, Reller LB, et al. A five-year multi-center study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamycins, penicillins, clindamycin, and metronidazole in the United States. Diagn Microbiol Infect Dis 1994; 18: 235–41
Selkon JB. The need for and choice of chemotherapy for anaerobic infections. Scand J Infect Dis 1981; Suppl. 26: 19–23
Sigeti JS, Guiney Jr DG, Davis CE. Mechanism of action of metronidazole on Bacteroides fragilis. J Infect Dis 1983; 148: 1083–9
Scher KS. Emergence of antibiotic resistant strains of Bacteroides fragilis. Surg Gyn Obstet 1988; 167: 175–9
Jokipii AMM, Jokipii L. Bactericidal activity of tinidazole. Chemotherapy 1977; 23: 25–31
Dornbusch K, Nord CE, Olsson-Liljeqvist. Antibiotic susceptibility of anaerobic bacteria with special reference to Bacteroides fragilis. Scand J Infect Dis 1979; Suppl. 19: 17–25
Heizmann WR, Schmid R, Heilmann R, et al. Association experiments with aerobic and anaerobic pathogens: a model of in vitro susceptibility testing in mixed infections: activity of enoxacin, clindamycin, and metronidazole. Infection 1989; 17: 160–4
Appelbaum PC, Spangler SK, Jacobs MR. β-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother 1990; 34: 1546–50
Hill GB, Ayers OM, Everett BQ. Susceptibilities of anaerobic gram-negative bacilli to thirteen antimicrobials and β-lactamase inhibitor combinations. J Antimicrob Chemother 1991; 28: 855–67
Appelbaum MD, Heseltine PNR, Cherubin CE. Epidemiology, antimicrobial susceptibility, pathogenicity, and significance of Bacteroides fragilis group organisms isolated at Los Angeles County-University of Southern California Medical Center. Rev Infect Dis 1991; 13: 12–8
Aldridge KE, Henderberg A, Sanders CV. In vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents. J Antimicrob Chemother 1990; 26: 353–9
Aldridge KE. In vitro susceptibility of Bacteroides fragilis group strains from abscesses, body fluids and wound/tissue samples. Drug Invest 1992; 4 Suppl. 1: 1–6
Bourgault AM, Lamothe F, Hoban DJ, et al. Survey of Bacteroides fragilis group susceptibility patterns in Canada. Antimicrob Agents Chemother 1992; 36: 343–7
Whiting JL, Cheng N, Chow AW. Interactions of ciprofloxacin with clindamycin, metronidazole, cefoxitin, cefotaxime, and mezlocillin against gram-positive and gram-negative anaerobic bacteria. Antimicrob Agents Chemother 1987; 31: 1379–82
Wexler HM, Finegold SM. In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria. Antimicrob Agents Chemother 1988; 32: 601–4
Pankuch GA, Jacobs MR, Appelbaum PC. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin. Antimicrob Agents Chemother 1993; 37: 1649–54
O’Keefe JP, Troc KA, Thompson KA. Activity of metronidazole and its hydroxy and acid metabolites against clinical isolates of anaerobic bacteria. Antimicrob Agents Chemother 1982; 22: 426–30
Marrie TJ, Haldane EV, Swanter CA, et al. Susceptibility of anaerobic bacteria to nine antimicrobial agents and demonstration of decreased susceptibility of Clostridium perfringens to penicillin. Antimicrob Agents Chemother 1981; 19: 51–5
Jones BM, Geary I, Alawattegama AB, et al. In-vitro and in-vivo activity of metronidazole against Gardnerella vaginalis, Bacteroides spp. and Mobiluncus spp. in bacterial vaginosis. J Antimicrob Chemother 1985; 16: 189–97
Chow AW, Patten V, Guze LB. Susceptibility of anaerobic bacteria to metronidazole: relative resistance of non-spore-forming gram-positive bacilli. J Infect Dis 1975; 131: 182–5
McNulty CAM, Dent J, Wise R. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob Agents Chemother 1985; 28: 837–8
Nagate T, Numata K, Hanada K, et al. The susceptibility of Campylobacter pylori to antiulcer agents and antibiotics. J Clin Gastroenterol 1990; 12 Suppl. 1: S135–8
Knapp CC, Ludwig MD, Washington JA. In vitro activity of metronidazole against Helicobacter pylori as determined by agar dilution and agar diffusion. Antimicrob Agents Chemother 1991; 35: 1230–1
Lopez-Brea M, Martin E, Lopez-Lavid C, et al. Susceptibility of Helicobacter pylori to metronidazole. Eur J Clin Microbiol Infect Dis 1991; 10: 1082–3
Pavicic MJAMP, van Winkelhoff AJ, de Graaff J. Synergistic effects between amoxicillin, metronidazole, and the hydroxymetabolite of metronidazole against Actinobacillus actinomycetemcomitans. Antimicrob Agents Chemother 1991; 35: 961–6
Pavicic MJAMP, van Winkelhoff AJ, de Graaff J. In vitro susceptibilities of Actinobacillus actinomycetemcomitans to a number of antimicrobial combinations. Antimicrob Agents Chemother 1992; 36: 2634–8
Jokipii AMM, Jokipii L. Comparative activity of metronidazole and tinidazole against Clostridium difficile and Peptostreptococcus anaerobius. Antimicrob Agents Chemother 1987; 31: 183–6
Traub WH. Clostridium perfringens type A: comparison of in vitro and in vivo activity of twelve antimicrobial drugs. Chemotherapy 1986; 32: 59–67
Traub WH, Karthein J, Spohr M. Susceptibility of Clostridium perfringens type A to 23 antimicrobial drugs. Chemotherapy 1986; 32: 439–45
Hof H, Sticht-Groh V. Antibacterial effects of niridazole: its effect on microaerophilic campylobacter. Infection 1984; 12: 36–9
Freydiere AM, Gille Y, Tigaud S, et al. In vitro susceptibilities of 40 Campylobacter fetus subsp. jejuni strains to niridazole and metronidazole. Antimicrob Agents Chemother 1984; 25: 145–6
Kharsany ABM, Hoosen AA, van den Ende J. Antimicrobial susceptibilities of Gardnerella vaginalis. Antimicrob Agents Chemother 1993; 37: 2733–5
Easmon CS, Ison CA, Kaye CM, et al. Pharmacokinetics of metronidazole and its principal metabolites and their activity against Gardnerella vaginalis. Br J Vener Dis 1982; 58: 246–9
Bannatyne RM, Jackowski J, Cheung R, et al. Susceptibility of Gardnerella vaginalis to metronidazole, its bioactive metabolites, and tinidazole. Am J Clin Path 1987; 87: 640–1
Weinberger M, Wu T, Rubin M, et al. Leptotrichia buccalis bacteremia in patients with cancer: report of four cases and review. Rev Infect Dis 1991; 13: 201–6
Davies AH. Metronidazole in human infections with syphilis. Br J Vener Dis 1967; 43: 197–200
Lau AH, Lam NP, Piscitelli SC. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 1992; 23: 328–64
Loft S, Døssing M, Poulsen HE, et al. Influence of dose and route of administration on disposition of metronidazole and its major metabolites. Eur J Clin Pharmacol 1986; 30: 467–73
Jensen JC, Gugler R. Single and multiple-dose metronidazole kinetics. Clin Pharmacol Ther 1983; 34: 481–7
Bergan T, Arnold E. Pharmacokinetics of metronidazole in healthy volunteers after tablets and suppositories. Chemotherapy 1980; 26: 231–41
Houghton GW, Thorne PS, Smith J, et al. Comparison of pharmacokinetics of metronidazole in healthy female volunteers following either a single oral or intravenous dose. Br J Clin Pharmacol 1979; 8: 337–41
Houghton GW, Smith J, Thorne, PS, et al. The pharmacokinetics of oral and intravenous metronidazole in man. J Antimicrob Chemother 1979; 5: 621–3
Bergan T, Leinebø O, Blom-Hagen T, et al. Pharmacokinetics and bioavailability of metronidazole after tablets, suppositories and intravenous administration. Scand J Gastroenterol 1984; 19 Suppl. 91: 45–60
Ralph ED, Clarke JT, Libke RD, et al. Pharmacokinetics of metronidazole as determined by bioassay. Antimicrob Agents Chemother 1974; 6: 691–6
Mattila J, Männistö PT, Mäntylä R, et al. Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. Antimicrob Agents Chemother 1983; 23: 721–5
Houghton GW, Thome PS, Smith J, et al. Plasma metronidazole concentrations after suppository administration. In: Phillips I, Collier J, editors. Metronidazole: proceedings of the Second International Symposium on Anaerobic Infections; 1979 Apr: Geneva. London (Academic Press), New York (Grune and Stratton): Royal Society of Medicine, 1979: 41–4
Cunningham FE, Kraus DM, Brubaker L, et al. Pharmacokinetics of intravaginal metronidazole gel. J Clin Pharmacol 1994; 34: 1060–5
Alper MM, Barwin N, McLean WM, et al. Systemic absorption of metronidazole by the vaginal route. Obstet Gynecol 1985; 65: 781–4
Aronson IK, Rumsfield JA, West DP, et al. Evaluation of topical metronidazole gel in acne rosacea. Drug Intell Clin Pharm 1987; 21: 346–51
Schmadel LK, McEvoy GK. Topical metronidazole: a new therapy for rosacea. Clin Pharm 1990; 9: 94–101
Taylor Jr JA, Migliardi JR, Schach von Wittenau M. Tinidazole and metronidazole pharmacokinetics in man and mouse. Antimicrob Agents Chemother 1969: 267–70
Schwartz DE, Jeunet F. Comparative pharmacokinetic studies of ornidazole and metronidazole in man. Chemotherapy 1976; 22: 19–29
Lau AH, Emmons K, Seligsohn R. Pharmacokinetics of intravenous metronidazole at different dosages in healthy subjects. Int J Clin Pharmacol Ther Toxicol 1991; 29: 386–90
Amon I, Amon K, Hüller H. Pharmacokinetics and therapeutic efficacy of metronidazole at different dosages. Int J Clin Pharmacol 1978; 16: 384–6
Hand WL, King-Thompson N, Holman JW. Entry of roxithromycin (RU 965), imipenem, cefotaxime, trimethoprim, and metronidazole into human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1987; 31: 1553–7
O’Grady LR, Ralph ED. Anaerobic meningitis and bacteremia caused by Fusobacterium species. Am J Dis Child 1976; 130: 871–3
Soriano F, Aguado JM, Tornero J, et al. Bacteroides fragilis meningitis successfully treated with metronidazole after a previous failure with thiamphenicol. J Clin Microbiol 1986; 24: 472–3
Visser AA, Hundt HKL. The pharmacokinetics of a single intravenous dose of metronidazole in pregnant patients. J Antimicrob Chemother 1984; 13: 279–83
Templeton R. Metabolism and pharmacokinetics of metronidazole: a review. In: Finegold SM, McFadzean JA, Roe FJC, editors. Proceedings of the International Metronidazole Conference; 1976 May; Montreal. Amsterdam: Excerpta Medica, 1977: 28–48
Elder MG, Kane JL. The pelvic tissue levels achieved by metronidazole after single or multiple dosing — oral and rectal. In: Phillips I, Collier J, editors. Metronidazole: proceedings of the Second International Symposium on Anaerobic Infections; 1979 Apr: Geneva. London (Academic Press), New York (Grune and Stratton): Royal Society of Medicine, 1979: 55–8
Berger SA, Kupferminc M, Lessing JB, et al. Penetration of clindamycin, cefoxitin, and metronidazole into pelvic peritoneal fluid of women undergoing diagnostic laparoscopy. Anti-microb Agents Chemother 1990; 34: 376–7
Büchler M, Malfertheiner P, Friess H, et al. The penetration of antibiotics into human pancreas. Infection 1989; 17: 26–31
Kling PA, Burman LG. Serum and tissue pharmacokinetics of intravenous metronidazole in surgical patients. Acta Chir Scand 1989; 155: 347–50
Andersson KE. Pharmacokinetics of nitroimidazoles: spectrum of adverse reactions. Scand J Infect Dis 1981; Suppl. 26: 60–7
Ralph ED, Kirby WMM. Bioassay of metronidazole with either anaerobic or aerobic incubation. J Infect Dis 1975; 132: 587–91
Nilsson-Ehle I, Ursing B, Nilsson-Ehle P. Liquid Chromatographic assay for metronidazole and tinidazole: pharmacokinetic and metabolic studies in human subjects. Antimicrob Agents Chemother 1981; 19: 754–60
Ti TY, Lee HS, Khoo YM. Disposition of intravenous metronidazole in Asian surgical patients. Antimicrob Agents Chemother 1996; 40: 2248–51
Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis 1991; Suppl. 74: 63–70
Nix DE, Tyrrell R, Müller M. Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis. Antimicrob Agents Chemother 1995; 39: 1848–52
Catterall RD. Trichomonal infections of the genital tract. Med Clin North Am 1972; 56: 1203–9
Csonka GW. Trichomonal vaginitis treated with one dose of metronidazole. Br J Vener Dis 1971; 47: 456–8
Morton, RS. Metronidazole in the single-dose treatment of trichomoniasis in men and women. Br J Vener Dis 1972; 48: 525–7
Underhill RA, Peck JE. Causes of therapeutic failure after treatment of trichomonal vaginitis with metronidazole: comparison of single-dose treatment with a standard regimen. Br J Clin Pract 1974; 28: 134–6
Grossman JH, Galask RP. Persistent vaginitis caused by metronidazole-resistant trichomonas. Obstet Gynecol 1990; 76: 521–2
Ahmed-Jushuf IH, Murray AE, McKeown J. Managing trichomonal vaginitis refractory to conventional treatment with metronidazole. Genitourin Med 1988; 64: 25–9
Dombrowski MP, Sokol RJ, Brown WJ, et al. Intravenous therapy of metronidazole-resistant Trichomonas vaginalis. Obstet Gynecol 1987; 69: 524–5
Tidwell BH, Lushbaugh WB, Laughlin MD, et al. A double-blind placebo-controlled trial of single-dose intravaginal versus single-dose oral metronidazole in the treatment of trichomonal vaginitis. J Infect Dis 1994; 170: 242–6
Thomason JL, Gelbart SM, Scaglione NJ. Bacterial vaginosis: current review with indications for asymptomatic therapy. Am J Obstet Gynecol 1991; 165: 1210–7
Joesoef MR, Schmid GP. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1995; 20 Suppl. 1: S72–9
Majeroni BA. New concepts in bacterial vaginosis. Am Fam Pract 1991; 44: 1215–8
Sweet RL. Role of bacterial vaginosis in pelvic inflammatory disease. Clin Infect Dis 1995; 20 Suppl. 2: S271–5
Hillier SL. Diagnostic microbiology of bacterial vaginosis. Am J Obstet Gynecol 1993; 169: 455–9
Lugo-Miro VI, Green M, Mazur L. Comparison of different metronidazole therapeutic regimens for bacterial vaginosis: a meta-analysis. JAMA 1992; 268: 92–5
Hillier SL, Lipinski C, Briselden AM, et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis. Obstet Gynecol 1993; 81: 963–7
Livengood CH, McGregor JA, Soper DE, et al. Bacterial vaginosis: efficacy and safety of intravaginal metronidazole treatment. Am J Obstet Gynecol 1994; 170: 759–64
Ferris DG, Litaker MS, Woodward L, et al. Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream. J Fam Pract 1995; 41: 443–9
Mikamo H, Izumi K, Ito K, et al. Study of treatment of bacterial vaginosis with the oral administration of metronidazole or cefdinir. Chemotherapy 1994; 40: 362–8
Boeke AJ, Dekker JH, van Eijk JTM, et al. Effect of lactic acid suppositories compared with oral metronidazole and placebo in bacterial vaginosis: a randomised clinical trial. Genitourin Med 1993; 69: 388–92
Wathne B, Holst E, Hovelius B, et al. Erythromycin versus metronidazole in the treatment of bacterial vaginosis. Acta Obstet Gynaecol Scand 1993; 72: 470–4
Covino JM, Black JR, Cummings M, et al. Comparative evaluation of ofloxacin and metronidazole in the treatment of bacterial vaginosis. Sex Transm Dis 1993; 20: 262–4
Schmitt C, Sobel JD, Meriwether C. Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole. Obstet Gynecol 1992; 79: 1020–3
Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin. J Infect Dis 1993; 167: 783–4
Fischbach F, Petersen EE, Weissenbacher ER, et al. Efficacy of clindamycin cream versus oral metronidazole in the treatment of bacterial vaginosis. Obstet Gynecol 1993; 82: 405–10
Andres FJ, Parker R, Hosein I, et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial. South Med J 1992; 85: 1077–80
Greaves WL, Chungafung J, Morris B, et al. Clindamycin versus metronidazole in the treatment of bacterial vaginosis. Obstet Gynecol 1988; 72: 799–802
McDonald HM, O’Loughlin JA, Vigneswaran R, et al. Bacterial vaginosis in pregnancy and efficacy of short-course oral metronidazole treatment: a randomized controlled trial. Obstet Gynecol 1994; 84: 343–8
Morales WJ, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol 1994; 171: 345–9
Hauth JC, Goldenberg Rl, Andrews WW, et al. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 1995; 333: 1732–6
Vejtorp M, Bollerup AC, Vejtorp L, et al. Bacterial vaginosis: a double-blind randomized trial of the effect of treatment of the sexual partner. Br J Obstet Gynaecol 1988; 95: 920–6
Mengel MB, Berg AO, Weaver CH, et al. The effectiveness of single-dose metronidazole therapy for patients and their partners with bacterial vaginosis. J Fam Pract 1989; 28: 163–71
Larsson P-G. Bacterial vaginosis treatment evaluation before one month is not accurate [letter]. Am J Obstet Gynecol 1995; 172: 1638–9
Piper M, Mitchell EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol 1993; 82: 348–52
Murphy PA, Jones E. Use of metronidazole in pregnancy: risks, benefits, and practice guidelines. J Nurse Midwifery 1994; 39: 214–20
Larsson P-G, Platz-Christensen J-J, Thejls H, et al. Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study. Am J Obstet Gynecol 1992; 166: 100–3
Pulkkinen P, Saranen M, Kaaja R. Metronidazole combined with nystatin (vagitories) in the prevention of bacterial vaginosis after initial treatment with oral metronidazole. Gynecol Obstet Invest 1993; 36: 181–4
Morris A, Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 1987; 82: 192–9
Sarosiek J, Slomiany A, Slomiany BL. Evidence for weakening of gastric mucus integrity by Campylobacter pylori. Scand J Gastroenterol 1988; 23: 585–90
Blaser MJ. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis 1990; 161: 626–33
Ormand JE, Tally NJ. Helicobacter pylori: controversies and an approach to management. Mayo Clin Proc 1990; 65: 414–26
NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease [editorial]. JAMA 1994; 272: 65–9
Soll AH. Medical treatment of peptic ulcer disease: practice guidelines. JAMA 1996; 275: 622–9
Goodard AF, Logan RPH. Antimicrobial resistance and Helicobacter pylori. J Antimicrob Chemother 1996; 37: 639–43
Noach LA, Langenberg WL, Bertola MA, et al. Impact of metronidazole resistance on the eradication of Helicobacter pylori. Scand J Infect Dis 1994; 26: 321–7
Rautelin H, Seppala K, Renkonen O, et al. Role of metronidazole in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother 1992; 36: 163–6
Thijs JC, Van Zwet AV, Oey HB. Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori. Scand J Gastroenterol 1993; 28: 934–8
Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol 1993; 88: 505–10
Borody TJ, Brandi S, Andrews P, et al. Use of high efficacy, lower dose triple therapy to reduce side effects of eradicating Helicobacter pylori. Am J Gastroenterol 1994; 89: 33–8
Logan RPH, Gummett PA, Misiewicz JJ, et al. One week eradication regimen for Helicobacter pylori. Lancet 1991; 338: 1249–52
Seppälä K, Färkkilä H, Nuutinen H, et al. Triple therapy of Helicobacter pylori infection in peptic ulcer. Scan J Gastroenterol 1992; 27: 973–6
Logan RPH, Gummett PA, Misiewicz JJ, et al. One week’s anti-Helicobacter pylori treatment for duodenal ulcer. Gut 1994; 35: 15–8
Graham DY, Lew GM, Klein PD et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. Ann Intern Med 1992; 116: 705–8
Sung JJ, Chung S, Thomas KW, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995; 332: 139–42
Bell GD, Powell KU, Burridge SM, et al. Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens. Q J Med 1993; 86: 743–50
Goh KL, Peh SC, Parasakthi N, et al. Omeprazole 40mg o.m. combined with amoxycillin alone or with amoxycillin and metronidazole in the eradication of Helicobacter pylori. Am J Gastroenterol 1994; 89: 1789–92
Karita M, Morshed MG, Ouchi K, et al. Bismuth triple therapy for eradicating Helicobacter pylori and reducing the gastric ulcer recurrence rate. Am J Gastroenterol 1994; 89: 1032–5
Saberi-Firoozi M, Massarrat S, Zare S, et al. Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized, controlled study. Am J Gastroenterol 1995; 90; 1419–23
Thijs JC, Van Zweet AA, Moolenaar W, et al. Triple therapy vs. amoxicillin plus omeprazole for treatment of helicobacter pylori infection: a multicenter, prospective, randomized controlled study of efficacy and side effects. Am J Gastroenterol 1996; 91: 93–7
Tucci A, Corinaldesi R, Stanghellini V, et al. One-day therapy for treatment of Helicobacter pylori infection. Digest Dis Sciences 1993; 38: 1670–3
Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308–12
Hosking SW, Ling TK, Chung SC, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 1994; 343: 508–10
Sung JY, Leung VK, Chung SC, et al. Triple therapy with sucralfate, tetracycline, and metronidazole for Helicobacter pylori-associated duodenal ulcers. Am J Gastroenterol 1995; 90: 1424–27
Borody TJ, Andrews P, Fracchia G. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 1995; 37: 477–81
Archimandritis A, Balatsos V, Delis V, et al. Triple therapy eradicated H. pylori equally in patients pretreated with omeprazole or ranitidine. J Clin Gastroenterol 1995; 20: 12–6
Labenz J, Gyenes E, Ruhl GH, et al. Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. Gut 1993; 34: 1167–70
Vaz Coelho LG, Passos MC, Chausson Y, et al. Five-day bismuth-free triple therapy for eradication of Helicobacter pylori and reduction in duodenal ulcer relapse. Am J Gastroenterol 1991; 86: 971–5
Ozmen MM. Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication? Am J Gastroenterol 1995; 90: 1542–3
Gotz JM, Veenendaal M, Veselic M, et al. Triple therapy with ranitidine clarithromycin and metronidazole in the treatment of Helicobacter pylori. Scand J Gastroenterol 1995; 30(S212): 34–7
Adamek RJ, Opferkuch W, Wegener M. Modified short-term triple therapy — ranitidine, clarithromycin, and metronidazole — for cure of Helicobacter pylori infection. Am J Gastroenterol 1995; 90: 168–9
Van Kruiningen HJ. On the use of antibiotics in Crohn’s disease. J Clin Gastroenterol 1995; 20: 310–6
Sachar DB. Maintenance therapy in ulcerative colitis and Crohn’s disease. J Clin Gastroenterol 1995; 20: 117–22
Ursing B, Kamme C. Metronidazole for Crohn’s disease. Lancet 1975; I: 775–7
Allan R, Cooke WT. Evaluation of metronidazole in the management of Crohn’s disease. Gut 1977; 18: 422
Davies PS, Rhodes J, Heatly RV, et al. Metronidazole in the treatment of chronic proctitis: a controlled trial. Gut 1977; 18: 680–1
Ambrose NS, Allan RN, Keighley MS. et al. Antibiotic therapy for treatment in relapse of intestinal Crohn’s disease. Dis Colon Rectum 1985; 28: 81–5
Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index: National Cooperative Crohn’s Disease study. Gastroenterol 1976; 70: 439–44
Scheurlen C, Kruis W, Spengler U, et al. Crohn’s disease is frequently complicated by giardiasis. Scand J Gastroenterol 1988; 23: 833–9
Blichfeldt P, Blomhoff J, Myhre E, et al. Metronidazole for Crohn’s disease: a double-blind crossover clinical trial. Scand J Gastroenterol 1978; 13: 123–7
Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perineal Crohn’s disease with metronidazole. Gastroenterol 1980; 79: 357–65
Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterol 1982; 83: 383–7
Jakobovits J, Schuster MM. Metronidazole therapy for active Crohn’s disease and associated fistulae. Am J Gastroenterol 1984; 79: 533–40
Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the cooperative Crohn’s disease study in Sweden: II. Results. Gastroenterol 1982; 83: 550–62
Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut 1991; 32: 1071–5
Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole for the prevention of Crohn’s recurrence after ileal resection. Gastroenterol 1995; 108: 1617–21
Prantera C, Kohn A, Zannoni F, et al. Metronidazole plus ciprofloxacin in the treatment of active, refractory Crohn’s disease: results of an open study. J Clin Gastrointerol 1994; 19: 79–88
Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole and ciprofloxacin. Am J Gastroenterol 1996; 91: 328–32
Davidson RA. Issues in clinical parasitology: the treatment of giardiasis. Am J Gastroenterol 1984; 79: 256–61
Shepherd RW, Boreham PFL. Recent advances in the diagnosis and management of giardiasis. Scand J Gastroenterol 1989; 169: 60–4
Wolfe MS. Giardiasis. Clin Microbiol Rev 1992; 93–100
Babb RR. Giardiasis. Postgrad Med 1995; 98: 155–8
Speelman P. Single-dose tinidazole for the treatment of giardiasis. Antimicrob Agents Chemother 1985; 27: 227–9
Jokipii L, Jokipii AMM. Single dose metronidazole and tinidazole as therapy for giardiasis: success rates, side effects and drug absorption and elimination. J Infect Dis 1979; 140: 984–8
Kyronseppa H, Pettersson T. Treatment of giardiasis: relative efficacy of metronidazole as compared with tinidazole. Scand J Infect Dis 1981; 13: 311–2
Dutta AK, Phadke MA, Bagade AC, et al. A randomized multicentre study to compare the safety and efficacy of albendazole and metronidazole in the treatment of giardiasis in children. Indian J Pediatr 1994; 61: 689–93
Misra PK, Kumar A, Agarwal V, et al. A comparative trial of albendazole verses metronidazole in giardiasis. Indian J Pediatr 1995; 32: 291–4
Oren B, Schgurensky E, Ephros M, et al. Single-dose ornidazole versus seven-day metronidazole therapy of giardiasis in kibbutzim children in Israel. Eur J Clin Microbiol Infect Dis 1991; 10: 963–5
Quiros-Buelna E. Furazolidone and metronidazole for the treatment of giardiasis in children. Scand J Gastroenterol 1989; 24 Suppl. 169: 65–9
Al-Waili N, Hasan N U. Mebendazole in giardial infection: a comparative study with metronidazole. J Infect Dis 1992; 165: 1170–1
Sullivan PB, Marsh MN, Dewit, et al. Prevalence and treatment of giardiasis in chronic diarrhoea and malnutrition. Arch Dis Child 1990; 65: 304–6
Taylor GD, Wenman WM, Tyrrell DL. Combined metronidazole and quinacrine hydrochloride therapy for chronic giardiasis. Can Med Assoc J 1987; 136: 1179–80
Popovic OS, Milovic V. Propranolol and metronidazole for the treatment of Metronidazole-resistant giardiasis. J Clin Gastroenterol 1990; 12: 604–5
Farthing MJG, Inge PMG, Perason RM. Effect of D-propranolol on growth and motility of flagellate protozoa. J Antimicrob Chemother 1987; 20: 519–22
Pothoulakis C, LaMont JT. Clostridium difficile colitis and diarrhea. Gastroenterol Clin North Am 1993; 22: 623–37
Fekety R, Shah AB. Diagnosis and treatment of Clostridium colitis. JAMA 1993; 269: 71–5
Kelly CP, Pothoulakis C, Lamont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257–62
Reinke CM, Messick CR. Update on Clostridium difficile-induced colitis, Part 1. Am J Hosp Pharm 1994; 51: 1771–81
Reinke CM, Messick CR. Update on Clostridium difficile-induced colitis, Part 2. Am J Hosp Pharm 1994; 51: 1892–901
Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995; 36: 673–9
Cozart JC, Kalangi SS, Clench MH, et al. Clostridium difficile diarrhea in patients with AIDS versus non-AIDS controls. J Clin Gastroenterol 1993; 16: 192–4
Teasley PG, Gerding DN, Olson MM, et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983; II: 1043–6
Johnson S, Homann SR, Betten KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or oral metronidazole. Ann Intern Med 1992; 117: 297–302
Oliva SL, Guglielmo BJ, Jacobs R, et al. Failure of intravenous vancomycin and intravenous metronidazole to prevent or treat antibiotic-associated pseudomembranous colitis. J Infect Dis 1989; 159: 1154–5
Johnson S, Peterson LR, Gerding DN. Intravenous metronidazole and Clostridium difficile-associated diarrhoea or colitis. J Infect Dis 1989; 160: 1087–8
Bolon RP, Culshaw MA. Fecal metronidazole concentrations during oral and intravenous therapy for antibiotic colitis due to Clostridium difficile. Gut 1986; 27: 1169–72
Cherry RD, Protney D, Jabbari M. Metronidazole: an alternative therapy for antibiotic-associated colitis. Gastroenterol 1982; 82: 849–51
Maltz G, Knauer CM. Amoebic liver abscess: a 15-year experience. Am J Gastroenterol 1991; 86: 704–10
Powell SJ, MacLeod I, Wilmot AJ, et al. Metronidazole in amoebic dysentery and amoebic liver abscess. Lancet 1966; 1: 1329–31
Sharma MP, Rai RR, Acharya SK, et al. Needle aspiration of amoebic liver abscess. BMJ 1989; 299: 1308–9
Irusen MF, Jackson TFHG, Simjee AE. Asymptomatic intestinal colonization by pathogenic Entamoeba histolytica in amebic liver abscess: prevalence, response to therapy, and pathogenic potential. J Infect Dis 1992; 14: 889–93
Meng XY, Wu JX. Perforated amebic liver abscess: clinical analysis of 110 cases. South Med J 1994; 87: 985–90
Tally FP, Sullivan CE. Metronidazole: in vitro activity, pharmacology and efficacy in anaerobic bacterial infections. Pharmacotherapy 1981; 1: 28–38
Paakkonen M, Alhava EM, Hurttunen R, et al. Piperacillin compared with cefuroxime plus metronidazole in diffuse peritonitis. Eur J Surg 1991; 157: 535–7
Dunn DL, Simmons RL. Empiric therapy of peritonitis and intraabdominal infection. Infect Surg 1983 Jul; 2: 466–83
Weinstein WM, Onderdonk AB, Bartlett JG, et al. Antimicrobial therapy of experimental intra-abdominal sepsis. J Infect Dis 1975; 132: 282–6
Nichols RL, Smith JW, Fossedal EN, et al. Efficacy of parenteral antibiotics in the treatment of experimentally induced intraabdominal sepsis. Rev Infect Dis 1979; 1: 301–12
Willis AT, Ferguson IR, Jones PH, et al. Metronidazole in prevention and treatment of bacteroides infections after appendectomy. BMJ 1976; 1: 318–21
Foster MC, Kapila L, Morris DL, et al. A randomized comparative study of sulbactam plus ampicillin vs. metronidazole plus cefotaxime in the management of acute appendicitis in children. Rev Infect Dis 1986; 8 Suppl. 5: S634–8
Paakkonen M, Alhava EM, Huttunen R, et al. Piperacillin compared with cefuroxime plus metronidazole in diffuse peritonitis. Eur J Surg 1991; 157: 535–7
Luke M, Iversen J, Sondergaard J, et al. Ceftriaxone/metronidazole is more effective than ampicillin/netilmicin/metronidazole in the treatment of bacterial peritonitis. Eur J Surg 1991; 157: 397–401
Harding GKM, Nicolle LE, Haase DA, et al. Prospective, randomized, comparative trials in the therapy for intraabdominal and female genital tract infections. Rev Infect Dis 1984; 6 Suppl. 1: S283–91
Kasholm B, Bartholdson P. Antibiotics in acute abdominal surgery. Acta Chir Scand 1986; 152: 267–72
Huizinga WKJ, Baker JW, Kadwa H, et al. Management of severe intra-abdominal sepsis: single agent antibiotic therapy with cefotetan versus combination therapy with ampicillin, gentamicin and metronidazole. Br J Surg 1988; 75: 1134–8
Yoshioka K, Youngs DJ, Keighley MRB. A randomised prospective controlled study of ciprofloxacin with metronidazole versus amoxicillin/clavulanic acid with metronidazole in the treatment of intra-abdominal infection. Infection 1991; 1: 25–9
Canadian Metronidazole-Clindamycin Study Group. Prospective, randomized comparison of metronidazole and clindamycin, each with gentamicin, for the treatment of serious intra-abdominal infection. Surgery 1983; 93: 221–9
Martin C, Sastre B, Mallet MN, et al. Pharmacokinetics and tissue penetration of a single 1000-milligram, intravenous dose of metronidazole for antibiotic prophylaxis of colorectal surgery. Antimicrob Agents Chemother 1991; 35: 2602–5
Gentry LO, Feliciano DV, Lea AS, et al. Perioperative antibiotic therapy for penetrating injuries of the abdomen. Ann Surg 1984; 200: 561–6
Nichols RL, Smith JW, Klein DB, et al. Risk of infection after penetrating abdominal trauma. N Engl J Med 1984; 311: 1065–70
Sims EH, Lou MA, Williams SW, et al. Piperacillin monotherapy compared with metronidazole and gentamicin combination in penetrating abdominal trauma. J Trauma 1993; 34: 205–10
Ingham HR, Selkon JB, Roxby CM. Bacteriological study of otogenic cerebral abscesses: chemotherapeutic role of metronidazole. BMJ 1977; 2: 991–3
Sjolin J, Lilja A, Eriksson N, et al. Treatment of brain abscess with cefotaxime and metronidazole: prospective study on 15 consecutive patients. Clin Infect Dis 1993; 17: 857–63
Chun CH, Johnson JD, Hofstetter M, et al. Brain abscess: a study of 45 consecutive cases. Medicine (Baltimore) 1986; 65: 415–31
Peterson DI, Voorhees EG, Elder HA. Bacteroides meningitis successfully treated with metronidazole. Ann Neurol 1979; 6: 364–5
Webber SA, Tuohy P. Bacteroides fragilis meningitis in a premature infant successfully treated with metronidazole. Pediatr Infect Dis J 1988; 7: 886–7
Spencer CH, Slusher CW, Sanders CV, et al. Fusobacterium necrophorum sepsis with cerebral infarction. South Med J 1989; 82: 1040–3
Kolander SA, Cosgrove EM, Molavi A. Clostridial endocarditis: report of a case caused by Clostridium bifermentans and review of the literature. Arch Intern Med 1989; 149: 455–6
Barrett AP. Metronidazole in the management of anaerobic neck infection in acute leukemia. Oral Surg Oral Med Oral Pathol 1988; 66: 287–9
Feng J, Austin TW. Anaerobic vertebral osteomyelitis. Can Med Assoc J 1991; 145: 132–3
Ramakrishnan KM, Jayaraman V, Ramachandran K, et al. The management of anaerobic infection in extensive burns. Burns 1986; 12: 270–2
Clarke JS, Condon RE, Bartlett JG, et al. Preoperative oral antibiotics reduce septic complications of colon operations: results of a prospective randomized, double-blind clinical study. Ann Surg 1977; 186: 251–9
McDonald PJ, Karran SJ, Chir M. A comparison of intravenous cefoxitin and a combination of gentamicin and metronidazole as prophylaxis in colorectal surgery. Dis Colon Rectum 1983; 26: 661–4
Karran SJ, Sutton G, Gartell P, et al. Imipenem prophylaxis in elective colorectal surgery. Br J Surg 1993; 80: 1196–8
Danziger L, Hassan E. Antimicrobial prophylaxis of gastrointestinal surgical procedures and treatment of intra-abdominal infections. Drug Intell Clin Pharm 1987; 21: 406–16
Rowe-Jones DC, Peel ALG, Kingston RD, et al. Single dose cefotaxime plus metronidazole versus three dose cefuroxime plus metronidazole as prophylaxis against wound infection in colorectal surgery: multicentre prospective randomised study. BMJ 1990; 300: 18–22
Rohwedder R, Bonadeo F, Benati M, et al. Single-dose oral ciprofloxacin plus parenteral metronidazole for perioperative antibiotic prophylaxis in colorectal surgery. Chemotherapy 1993; 39: 218–24
Morris WT. Ceftriaxone is more effective than gentamicin/metronidazole prophylaxis in reducing wound and urinary tract infections after bowel operations: results of a controlled, randomized, blind clinical trial. Dis Colon Rectum 1993; 36: 826–33
Johnson JT, Yu VL, Myers EN, et al. Efficacy of two third-generation cephalosporins in prophylaxis for head and neck surgery. Arch Otolaryngol 1984; 110: 224–7
Seagle MB, Duberstine LE, Gross CW, et al. Efficacy of cefazolin as prophylactic antibiotic in head and neck surgery. Otolaryngology 1979; 85: 568–72
Johnson JT, Myers EN, Thearle PB, et al. Antimicrobial prophylaxis for contaminated head and neck surgery. Laryngoscope 1982; 94: 46–51
Sawyer R. Clinical implications of metronidazole antianaerobic prophylaxis in major head and neck surgical procedures. Ear Nose Throat J 1988; 67: 655–62
Robbins KT, Byers RM, Cole MD, et al. Wound prophylaxis with metronidazole in head and neck surgical oncology. Laryngoscope 1988; 98: 803–6
Sawyer R, Cozzi L, Rosenthal DI, et al. Metronidazole in head and neck surgery — the effect of lengthened prophylaxis. Otolaryngol Head Neck Surg 1990; 103: 1009–11
Tandon DA, Laldina HC, Sundaram KR. Role of prophylactic antibiotics in surgery for advanced head and neck cancer. J Laryngol Otol 1992; 106: 621–4
Nielsen PG. Treatment of rosacea with 1% metronidazole cream: a double-blind study. Br J Dermatol 1983; 108: 327–32
Nielsen PG. A double-blind study of 1% metronidazole cream versus systemic oxytetracycline therapy for rosacea. Br J Dermatol 1983; 109: 63–5
Veien NK, Christiansen JV, Hjorth N, et al. Topical metronidazole in the treatment of rosacea. Cutis 1986; 38: 209–10
Bleicher PA, Charles JH, Sober AJ. Topical metronidazole therapy for rosacea. Arch Dermatol 1987; 123: 609–14
Lowe NJ, Hendersen T, Millikan LE, et al. Topical metronidazole for severe and recalcitrant rosacea: a prospective open trial. Cutis 1989; 43: 283–6
Signore RJ. A pilot study of 5 percent permethrin cream versus 0.75 percent metronidazole gel in acne rosacea. Cutis 1995; 56: 177–9
Eriksson G, Nord CE. Impact of topical metronidazole on the skin and colon microflora in patients with rosacea. Infection 1987; 15: 10–2
Nielsen PG. Topical metronidazole gel: use in acne vulgaris. Int J Dermatol 1991; 30: 662–6
Tong D, Peters W, Barnetson R St C. Evaluation of 0.75% metronidazole gel in acne — a double-blind study. Clin Exp Dermatol 1994; 19: 221–3
Veien NK, Munkvad JM, Nielsen AO, et al. Topical metronidazole in the treatment of perioral dermatitis. J Am Acad Dermatol 1991; 24: 258–60
Miller SR, Shatila AR. Topical metronidazole gel (0.75%) for the treatment of perioral dermatitis in children. J Am Acad Dermatol 1994; 31: 847–8
Witkowski JA, Parish LC. Topical metronidazole gel: the bacteriology of decubitus ulcers. Int J Dermatol 1991; 30: 660–1
Gerassimos JM, Hatzis A, Kontogiannis P, et al. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994; 89: 43–6
Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986; 27: 1210–2
Gilat T, Leichtman G, Delpre G, et al. A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis. J Clin Gastroenterol 1989; 11: 392–5
Madden MV, Mclntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994; 39: 1193–6
Nygaard K, Bergan T, Bjørneklett A, et al. Topical metronidazole treatment in pouchitis. Scand J Gastroenterol 1994; 29: 462–7
Banet DE, McClave SA, Callen JP. Oral metronidazole, an effective treatment for Sweet’s syndrome in a patient with associated inflammatory bowel disease. J Rheumatol 1994; 21: 1766–8
Wong W, Hodge MG, Lewis A, et al. Resolution of cyclosporin-induced gingival hypertrophy with metronidazole [letter]. Lancet 1994; 343: 986
Tak PP, Van Duinen CM, Bun P, et al. Pneumatosis cystoides intestinalis in intestinal pseudoobstruction: resolution after therapy with metronidazole. Dig Dis Sci 1992; 37: 949–54
van Winkelhoff AJ, Abbas F, Pavicic MJAMP, et al. Chronic conjunctivitis caused by oral anaerobes and effectively treated with systemic metronidazole plus amoxicillin. J Clin Microbiol 1991; 29: 723–5
Jauhonen P, Lehtola J, Karttunen T. Treatment of pneumatosis coli with metronidazole: endoscopie follow-up of one case. Dis Colon Rectum 1987; 30: 800–1
Wellis BW. Symptomatic treatment of primary pneumatosis coli with metronidazole. BMJ 1980; 280: 763–4
Laguna del Estai P, Moya MS, Martin T, et al. Metronidazole therapy for visceral leishmaniasis. Clin Infect Dis 1994; 19: 1161–2
Bjarnason I, Hayllar J, Smethurst P, et al. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut 1992; 33: 1204–8
James RE Malaria treated with emetine or metronidazole [letter]. Lancet 1985; II: 498
Pallangio KJ, Minjas JN, Sarda RK. Metronidazole for falciparum malaria [letter]. Lancet 1986; I: 922
Schattenkerk JKME, van Gool T, van Ketel RJ, et al. Clinical significance of small-intestinal microsporidiosis in HIV-1-infected individuals. Lancet 1991; 337: 895–8
Asmuth DM, DeGirolami PC, Federman M, et al. Clinical features of microsporidiosis in patients with AIDS. Clin Infect Dis 1994; 18: 819–25
Blanshard C, Gazzard BG. Microsporidiosis in HIV-1-infected individuals. Lancet 1991; 337: 1488–9
Weinstein MC, Read JL, MacKay DN, et al. Cost-effective choice of antimicrobial therapy for serious infections. J Gen Intern Med 1986; 1: 351–63
Earl P, Sisson PR, Ingham HR. Twelve-hourly dosage schedule for oral and intravenous metronidazole. J Antimicrob Chemother 1989; 23: 619–21
Freeman CD, Nightingale CH, Nicolau DP, et al. Serum bactericidal activity of ceftriaxone plus metronidazole against common intra-abdominal pathogens. Am J Hosp Pharm 1994; 51: 1782–7
Freeman CD, Nightingale CH, Nicolau DP, et al. Bactericidal activity of low-dose ceftizoxime plus metronidazole compared with cefoxitin and ampicillin-sulbactam. Pharmacotherapy 1994; 14: 185–90
Bunz D, Gupta S, Jewesson P. Metronidazole cost-containment: a two-stage intervention. Hosp Formul 1990; 25: 1167–77
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Freeman, C.D., Klutman, N.E. & Lamp, K.C. Metronidazole. Drugs 54, 679–708 (1997). https://doi.org/10.2165/00003495-199754050-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199754050-00003